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Abstract
Background: Polycystic ovary syndrome is a complex and heterogeneous disease leading to re-
productive, as well as metabolic problems. It has been suggested that there may be a genetic 
SUHGLVSRVLWLRQLQWKHDHWLRORJ\RISRO\F\VWLFRYDU\V\QGURPH7KHLGHQWLÀFDWLRQRIFDOSDLQ
gene (CAPN10)DVWKHÀUVWFDQGLGDWHJHQHIRUW\SHGLDEHWHVPHOOLWXVKDVIRFXVHGWKHLQWHUHVW
in investigating their possible connection with the polycystic ovary syndrome. This syndrome is 
associated with hyperinsulinaemia and insulin resistance, two metabolic abnormalities associ-
ated with type 2 diabetes mellitus.
Objective: To investigate if there is association between the SNP-63 and the genetic variant in-
del-19 of CAPN10 gene and polycystic ovary syndrome in women of reproductive age.
Material and methods: This study included 101 women (55 with polycystic ovary syndrome and 
ZLWKRXWSRO\F\VWLFRYDU\V\QGURPH7KHJHQHWLFYDULDQWLQGHOZDVLGHQWLÀHGE\HOHFWUR-
SKRUHVLVRIWKHDPSOLÀHGIUDJPHQWVE\3&5DQGWKH613E\3&55)/3
Results: 7KHDOOHOHDQGJHQRW\SHIUHTXHQFLHVRIWKHWZRYDULDQWVGRQRWGLIIHUVLJQLÀFDQWO\EH-
tween women with polycystic ovary syndrome and the control women group. The haplotype 21 
GHÀQHGE\WKHLQVHUWLRQDOOHOHRILQGHOYDULDQWDQG&DOOHOHRI613ZDVIRXQGZLWKKLJKHU
frequency in both study groups, being more frequent in the polycystic ovary syndrome patients 
JURXSKRZHYHUWKLVGLIIHUHQFHZDVQRWVWDWLVWLFDOO\VLJQLÀFDQW
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gotic twins2. The theories related to the inheritance mode 
of polycystic ovary syndrome include a multifactorial model 
where the interaction of environmental factors (nutrition 
and physical activity) and a group of causative genes (candi-
date susceptibility genes) contribute to its phenotypic vari-
ability6.
The association between polycystic ovary syndrome with 
insulin resistance and the risk of developing type 2 diabetes 
mellitus led to the assumption that the primary defect caus-
ing this syndrome was connected to one of the mediators of 
the insulin response metabolic pathway77KHLGHQWLÀFDWLRQ
of the calpain-10 gene (CAPN10) by Horikawa et al.8 in 2000 
DVWKHÀUVWJHQHUHODWHGWRW\SHGLDEHWHVPHOOLWXVWULJ-
gered interest to investigate its possible relation with poly-
cystic ovary syndrome, given the documented participation 
of the protein product of this gene in the insulin signalling 
pathway6,7,9-11.
Calpain-10 is a non-lysosomal cysteine-protease acti-
vated by calcium and an atypical calpain, since it lacks 
IV domain8,12. This calpain can be seen in different tis-
sues, such as pancreatic islets, the skeletal muscle, the 
liver and adipocytes13$OWKRXJKLWVVSHFLÀFIXQFWLRQKDV
not been fully described yet, it has been suggested that 
calpain-10 is an important molecule for the function of 
SDQFUHDWLFşFHOOVVLQFHLWKDVEHHQGHPRQVWUDWHGWRUHJ-
ulate the exocytosis of insulin secretory granules14,15. It 
has also been stated that calpain-10 facilitates the trans-
Background
Polycystic ovary syndrome is a heterogeneous endocrine 
disorder, considered to be the most common cause of an-
ovulation, hyperandrogenism and infertility in women of 
childbearing age1. Other major clinical characteristics of 
polycystic ovary syndrome also include obesity (mainly in 
the upper segment) and metabolic abnormalities, such as 
hyperinsulinaemia and insulin resistance, which is a risk fac-
tor for developing type 2 diabetes mellitus and cardiovascu-
lar disease2,3.
The prevalence of polycystic ovary syndrome in different 
populations is 3-7% in women of childbearing age and 60-
80% in women with hyperandrogenism4. In Mexico, a preva-
lence of 6% has been reported5.
The physiopathology of polycystic ovary syndrome is com-
plex. However, the 2 main hormonal changes observed in 
patients with polycystic ovary syndrome include increased 
circulating levels of the luteinising hormone and insulin (hy-
perinsulinaemia); in fact, it has been suggested that there 
is certain synergism between both, so ovarian hyperstim-
ulation due to insulin would lead to hyperandrogenism2. 
Polycystic ovary syndrome has been considered a disorder 
with a genetic component in its aetiology, and this condi-
tion has been supported by pronounced familial aggregation 
and by the documentation of the fact that the degree of 
concordance is higher in monozygotic twins than in dizy-
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Conclusions: The results suggest that SNP-63 and indel-19 variant of CAPN10 gene do not repre-
sent a risk factor for polycystic ovary syndrome in our patient group.
© 2015 Academia Mexicana de Cirugía A.C. Published by Masson Doyma México S.A. This is an open access 
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Análisis de asociación del SNP-63 y la variante indel-19 del gen de calpaína-10  
con síndrome de ovario poliquístico en mujeres en edad reproductiva
Resumen
Antecedentes: El síndrome de ovario poliquístico es una enfermedad compleja y heterogénea 
que implica problemas reproductivos y metabólicos. Se ha sugerido una predisposición gené-
WLFDHQODHWLRORJtDGHHVWHVtQGURPH/DLGHQWLÀFDFLyQGHOJHQGHODFDOSDtQD(CAPN10) 
como el primer gen asociado a diabetes mellitus tipo 2 suscitó el interés por investigar su 
posible relación con el síndrome de ovario poliquístico, debido a que este síndrome se asocia 
a hiperinsulinemia y resistencia a la insulina, 2 anormalidades metabólicas relacionadas con 
diabetes. 
Objetivo: Investigar si existe asociación entre el SNP-63 y la variante indel-19 del gen CAPN10 y 
el síndrome de ovario poliquístico en mujeres en edad reproductiva.
Material y métodos: El estudio incluyó a 101 mujeres (55 con síndrome de ovario poliquístico y 
FOtQLFDPHQWHVDQDV/DYDULDQWHLQGHOVHLGHQWLÀFyPHGLDQWHFRUULPLHQWRHOHFWURIRUpWLFR
GHORVIUDJPHQWRVDPSOLÀFDGRVSRU3&5\HO613SRU3&55)/3
Resultados:/DVIUHFXHQFLDVDOpOLFDV\JHQRWtSLFDVGHODVYDULDQWHVQRGLÀHUHQVLJQLÀFDWLYD-
mente entre pacientes con síndrome de ovario poliquístico y mujeres del grupo control. El ha-
SORWLSRGHÀQLGRSRUHODOHORLQVHUFLyQGHODYDULDQWHLQGHO\HODOHOR&GHO613VHHQ-
contró con mayor frecuencia en los 2 grupos de estudio, siendo más frecuente en el grupo de 
SDFLHQWHVVLQHPEDUJRHVWDGLIHUHQFLDQRIXHHVWDGtVWLFDPHQWHVLJQLÀFDWLYDS 
Conclusiones: Los resultados sugieren que el SNP-63 y la variante indel-19 del gen CAPN10 no 
son factores de riesgo para síndrome de ovario poliquístico en nuestro grupo de pacientes.
© 2015 Academia Mexicana de Cirugía A.C. Publicado por Masson Doyma México S.A. Este es un artículo 
Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The women from the control group were randomly 
selected and had regular menstrual cycles between 21-
28 days, with a body mass index < 25 and without personal 
or family history of polycystic ovary syndrome. They visited 
the hospital for a general medical examination.
The study did not include pregnant women or women un-
der anovulatory, antiandrogen or corticosteroid therapy. 
Confusion variables, such as physical activity and diet, were 
not taken into account for this study.
*HQRW\SLÀFDWLRQ
The genomic DNA was obtained from peripheral blood leu-
NRF\WHVDFFRUGLQJWRDVOLJKWO\PRGLÀHGVWDQGDUGSURWR-
col28, and it was stored in Tris-EDTA buffer with pH 8.0, at 
–20°C until its processing.
To identify the SNP-63 (C16378T), a fragment of 192 bp 
ZDVDPSOLÀHGDQGVXEMHFWHGWRGLJHVWLRQZLWK8RIWKH
restriction enzyme HhaI at 37°C, according to the manu-
IDFWXUHU·VLQVWUXFWLRQV1HZ(QJODQG%LRODEV,SVZLFK86
This resulted in 1 fragment of 192 bp in the presence of 
the T allele and 2 fragments, one of 162 bp and another 
one of 30 bp, in the presence of the C allele29. To iden-
tify the indel-19 variant, a fragment of 155 bp was ampli-
ÀHGLQWKHSUHVHQFHRIGHOHWLRQUHSHWLWLRQVRIES5
DOOHOHZKLOHDIUDJPHQWRIESZDVDPSOLÀHGLQWKH
presence of insertion (2 repetitions of 32 bp, 3R allele)29 
(Table 2). The difference in base pairs of CRP products and 
enzyme digestion products was analysed in 6% polyacryl-
amide gel, dyed with silver nitrate (Fig. 1). As an internal 
quality control, reference genotype samples were selected 
IRUFRQÀUPDWLRQE\FDSLOODU\HOHFWURSKRUHVLVLQDQDXWR-
matic sequencer - Beckman-Coulter, CEQ8800 model (Cali-
IRUQLD86
The haplotypes formed by 2 polymorphisms of the CAPN10 
gene were inferred considering the indel-19 variant in the 
ÀUVWSRVLWLRQDQG613LQWKHVHFRQGSRVLWLRQ7KLVUHVXOWV
in 4 possible haplotypes: haplotype 11 (deletion allele of 
the indel-19 variant, C allele of the SNP-63), haplotype 12 
(deletion allele of the indel-19 variant, T allele of the SNP-
63), haplotype 21 (insertion allele of the indel-19 variant, 
C allele of the SNP-63) and haplotype 22 (insertion allele of 
the indel-19 variant, T allele of the SNP-63).
Statistical analysis
The allelic frequencies of the 2 variants of the CAPN10 gene 
were determined using the direct counting method of ob-
served genotypes and were presented as simple frequen-
cies.
The comparison between allelic, genotypic and haplo-
type frequencies of the indel-19 variant and SNP-63 among 
patients with polycystic ovary syndrome and women from 
the control group, as well as the Hardy-Weinberg balance 
determination, were conducted using the chi-square test 
(X27KHUHVXOWZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQLÀFDQWLIWKH
probability value was lower than 0.05.
The data analysis was performed using the statistical pro-
gramme RxC with 10,000 iterations30. The programme Hap-
lotypeReconstructor_v0.6 was used to infer haplotypes.
ORFDWLRQRI*/87WKURXJKDGLVWDOHIIHFWRQWKHLQVXOLQ
action pathway. In addition, calpain-10 has also been in-
volved in the reorganisation of the actin cytoskeleton re-
ODWHGWRERWK*/87YHVLFOHWUDQVORFDWLRQDQGWRLQVXOLQ
secretion14,16.
The CAPN10 gene is located in the distal region of the 
long arm of chromosome 2 (2q37.3) and it is 65,674 nu-
cleotides long, which are distributed in 15 exons and 
14 introns14,16)URPWKHYDULDQWVLGHQWLÀHGLQWKHCAPN10 
gene, those that stand out are an SNP located in intron 3, 
the SNP-43 (G>A; rs3792267), and another one located 
in intron 13, the SNP-63 (C>T; rs5030952), as well as an 
insertion/deletion of 32 bp, referred to in the medical 
literature as SNP-19, found in intron 6 (indel-19 variant; 
rs3842570), since it has been described that, in an inde-
pendent manner or as an haplotype, these contribute to 
the susceptibility to type 2 diabetes mellitus in several 
populations8,17. Some studies have focused on the rela-
tion between polycystic ovary syndrome and the variants 
in CAPN101,6,9-11,18-24QHYHUWKHOHVVWKHLQÁXHQFHRIJHQHWLF
variations on the susceptibility to develop multifactorial 
pathologies, such as polycystic ovary syndrome, seems to 
vary among populations. Thus, the objective of this study 
was to analyse the distribution of alleles and genotypes 
of two of the most common variants of the CAPN10 gene 
(the SNP-63 and the indel-19 variant) in patients with poly-
cystic ovary syndrome and in women without polycystic 
ovary syndrome, so as to determine if there is a relation 
between this syndrome and the two variants in women of 
childbearing age.
Material and methods
The study involved a total of 101 women (55 diagnosed 
with polycystic ovary syndrome and 46 without polycystic 
ovary syndrome), all of whom were of childbearing age (18-
38 years) and not related to each other. The sample sizes 
for the 2 study groups (55 and 46) are above the minimum 
VXEMHFWVIRUDELDOOHOLFSRO\PRUSKLVPV\VWHPŞ
p = 0.05), according to Chakraborty25.
All the women included in the study were of mixed race 
and lived in the state of Jalisco. Prior to signing the Informed 
consent form for study participation, women who accepted 
to participate were informed about the purpose, the ben-
HÀWVDQGWKHSURFHGXUHVRIWKHSURMHFW7KHVWXG\SURWRFRO
was conducted pursuant to the Declaration of Helsinki and 
authorised by the Local Ethics and Research Committee of 
the Instituto Mexicano del Seguro Social (N.  2005/1/I/064).
Patients with polycystic ovary syndrome were subsequent-
ly recruited in the Fertility and Endocrinology departments 
RIWKH+LJKO\6SHFLDOLVHG0HGLFDO8QLWRIWKH*\QDHFRORJ\
and Obstetrics Hospital of the National Medical Centre of 
the West of the Mexican Social Security Institute. Poly-
cystic ovary syndrome was diagnosed in accordance with 
the Rotterdam ASRM/ESHRE consensus criteria, revised in 
200326, accompanied by the comprehensive management of 
polycystic ovary syndrome (clinical practice guideline, CIE-
10:E28, Mexican Social Security Institute)27 (Table 1). Out of 
55 patients with polycystic ovary syndrome, 44 were over-
weight (body mass index > 25) and 11 suffered from obesity 
ERG\PDVVLQGH[
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indel-19 variant and the C allele of the SNP-63 were more 
frequent in the group of patients with polycystic ovary syn-
drome compared to the control group. Nevertheless, this 
GLIIHUHQFHZDVQRWVWDWLVWLFDOO\VLJQLÀFDQWS DQG
S UHVSHFWLYHO\
The 4 possible haplotypes were observed in the study 
population. The combination 21 (insertion allele of the in-
del-19 variant, C allele of the SNP-63) and the haplodip-
lotype 21/21 were more frequent in the 2 study groups 
(Table 4). However, when comparing the observed frequen-
cies of the total haplotypes and haplodiplotypes between 
the group of patients with polycystic ovary syndrome and 
WKHFRQWUROJURXSWKHUHZHUHQRVWDWLVWLFDOO\VLJQLÀFDQWGLI-
IHUHQFHVS DQGS UHVSHFWLYHO\
In addition, the allelic frequencies of the indel-19 vari-
ant and SNP-63 observed in the studied population were 
compared with the frequencies described in other studies 
conducted in populations from America (Chile and Brazil), 
Results
The average age of women from the control group was 
26 years, and 80% of these women had menstrual cycles 
from 25 to 28 days. On the other hand, in patients with 
polycystic ovary syndrome, the average age was 29 years, 
and 88% of them had menstrual cycles from 30 to 60 days.
Table 3 shows the distribution of alleles and genotypes 
of SNP-63 and the indel-19 variant in patients with poly-
cystic ovary syndrome and women from the control group. 
The distribution of observed genotypes of the 2 variants was 
in accordance with the expected results from the Hardy-
Weinberg balance determination (p > 0.05). The genotypic 
frequencies of the indel-19 variant and SNP-63 show no sig-
QLÀFDQWGLIIHUHQFHVDPRQJWKHJURXSRISDWLHQWVZLWKSRO\-
cystic ovary syndrome and women from the control group 
S DQGS UHVSHFWLYHO\7KHDQDO\VLVRI
allelic frequencies showed that the insertion allele of the 
Table 1 Revised Rotterdam ESHRE/ASRM 2003 criteria, accompanied by CPG CIE-10: E28.
Diagnostic criteria (2 out of 3 criteria)
1. Oligo and/or anovulation History of 8 or less menstrual cycles within a year or menstrual cycles shorter 
than 26 days or longer than 35 days and P4 < 4 ng/ml
2. Signs of hyperandrogenism Clinical Hirsurtisma
Acne
Alopecia - male pattern
Biochemical Total testosterone > 84.7 ng/dl
Free testosterone > 0.75 ng/dl
Free testosterone/androgen index
DHEA
DHEAS > 2,459 ng/ml
LH/FSH relation > 2
Lower levels of sexual-steroid transporting globulin
3. Polycystic ovaries Presence of 12 or more follicles in each ovary with a diameter from 2 to 9 mm and/
or increased ovarian volume > 10 mm (ultrasound assessment)
Exclusion of other pathologiesb
Syndromes of severe insulin resistance Cushing’s syndrome
HAIRAN
Androgen secreting neoplasm 
Congenital adrenal hyperplasia 'HÀFLHQF\RIK\GUR[\ODVHK\GUR[\SURJHVWHURQHQJPO
Androgen secreting tumours Sertoli-Leydig tumours, adrenal adenomas 
Hyperprolactinaemia Increased levels of prolactin
Hypogonadotropic hypogonadism Low serum levels of FSH and reduced E2 levels
Premature ovarian failure Increased serum levels of FSH and reduced E2 levels
Complementary studies for the assessment of comorbidities 
)DVWLQJOLSLGSURÀOH
Fasting serum glucose
Fasting serum insulin
Glucose/insulin ratio < 4.5 indicates insulin resistance
DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulphate; E2: estradiol; FSH: follicle-stimulating hormone; HAIRAN: 
hyperandrogenism, insulin resistance and acanthosis nigricans syndrome; LH/FSH: luteinising hormone/follicle-stimulating hormone 
ratio; P4: progesterone.
a Assessed using a standardised scoring system (Ferriman-Gallwey).
b The exclusion of other pathologies is part of the initial assessment. Revised Rotterdam ESHRE/ASRM 2003 criteria26. Comprehensive 
management of polycystic ovary syndrome27.
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the CAPN10 gene were analysed (SNP-44 and SNP-43), and 
none of the 4 variants was associated with polycystic ovary 
syndrome. Though there are several studies that show the 
involvement of variants in the CAPN10 gene in the devel-
opment of the polycystic ovary syndrome, the association 
is not always made with the same variant, given that, for 
instance, in German women, this syndrome was associated 
with SNP-5611; in women from Spain6, Turkey19 and India1, it 
was associated with SNP-44. Furthermore, in 2 populations 
of Latin America, Chile20 and Brazil21, the syndrome was as-
sociated with SNP-43.
There are relatively few studies that investigated the 
relation between polycystic ovary syndrome and the hap-
lotypes of the CAPN10 gene. In a study conducted in Ger-
man women, in which 8 variants of the CAPN10 gene were 
analysed (including indel-19 and SNP-63), it was found that 
haplotype TGA2AGCA represents a higher risk for polycys-
tic ovary syndrome11. In women from India, where 5 vari-
ants were analysed (also including indel-19 and SNP-63), 
WKHUHZDVDVLJQLÀFDQWDVVRFLDWLRQZLWKKDSORW\SH1. 
In Spanish women, where 4 variants were analysed (SNP-
44, SNP-43, indel-19 and SNP-43), haplotype 1121 was 
Asia (China, Korea, India and Turkey) and Europe (Germany, 
Spain and England) (Table 5).
Discussion
The association between polycystic ovary syndrome with 
insulin resistance and the risk for developing type 2 diabe-
tes mellitus has been described. This study was conducted 
to assess the possible association between this syndrome 
and 2 polymorphisms of the CAPN10 gene (indel-19 variant 
and SNP-63) involved in the risk haplotype (121) for type 
2 diabetes mellitus in Mexican-Americans8. It was found 
that the distribution of alleles and genotypes was similar in 
patients with polycystic ovary syndrome and women with-
out polycystic ovary syndrome, which makes it possible to 
suggest that, in our group of patients, the indel-19 variant 
and SNP-63 do not represent a risk factor for developing 
polycystic ovary syndrome. This finding is in accordance 
with the results from 2 previous studies, one conducted in 
England9 and the other in Turkey18, where, apart from ana-
lysing SNP-63 and the indel-19 variant, 2 other variants of 
Tabla 2 $ERUGDMHPHWRGROyJLFRSDUDODLGHQWLÀFDFLyQGHODVGRVYDULDQWHVGHOJHQCAPN10.
Variante Iniciadores Fragmento 
DPSOLÀFDGR
Enzima de 
restricción
Fragmentos 
esperados
SNP-63 Sentido
5’AAGGGGGGCCAGGGCCTGACGGGGGTGGCG3’
Antisentido
5’AGCACTCCCAGCTCCTGATC3’
192 pb HhaI
GCG^C
Alelo C 162 +30 pb
Alelo T 192 pb
Indel-19
inserción/
deleción 
de 32 pb
Sentido
5’GTTTGGTTCTCTTCAGCGTGGAG3
Antisentido
5’CATGAACCCTGGCAGGGTCTAAG3’
155 pb
187 pb
– Alelo Ins 187 pb
Alelo Del 155 pb
pb: pares de bases.
Fig. 1 $*HQRW\SLÀFDWLRQRIWKHLQGHOYDULDQW&53SURGXFWVVHSDUDWHGLQSRO\DFU\ODPLGHJHOG\HGZLWKVLOYHUQLWUDWH0
molecular weight marker (DNA ladder of 50 bp). Lanes 1 and 3 homozygous Ins/Ins (fragment of 187 bp); lanes 2 and 5 heterozygous 
,QV'HOIUDJPHQWVRIESDQGESODQHKRPR]\JRXV'HO'HOIUDJPHQWRIES%*HQRW\SLÀFDWLRQRI613&53
products digested with the Hha1 enzyme, separated in 6% polyacrylamide gel, dyed with silver nitrate. M: molecular weight marker 
(DNA ladder of 50 bp). Lanes 3 and 6 homozygous C/C (fragment of 162 bp); lanes 1, 4 and 7 heterozygous C/T (fragments of 192 bp 
and 162 bp); lanes 2 and 5 homozygous T/T (fragment of 192 bp).
M 1 2 3 4 5
Ins/Ins Ins/Del Ins/Ins Del/Del Ins/Del
M 1 2 3 4 5 6 7
C/T T/T C/C C/T T/T C/C C/T
187 pb
A B
155 pb
192 pb
162 pb
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Nevertheless, no statistically significant value was ob-
tained when comparing haplotype frequencies with the 
control group, so its possible association with polycystic 
ovary syndrome was discarded in our group of patients 
studied. Therefore, it is necessary to analyse other vari-
ants in the CAPN10 gene to investigate the contribution 
of an extended haplotype to the development of this syn-
drome.
Although our results suggest the lack of involvement in 
the development of polycystic ovary syndrome of the in-
del-19 variant and SNP-63 of the CAPN10 gene, both in an 
individual manner and as haplotype, this study is particu-
larly important given that, to the best of our knowledge, it 
LVWKHÀUVWVWXG\WKDWLQYHVWLJDWHVWKHSRVVLEOHDVVRFLDWLRQ
of variants of the CAPN10 gene and haplotypes to polycystic 
ovary syndrome in the Mexican population.
The comparative analysis of allelic frequencies among 
the different populations demonstrated that allelic fre-
quencies of the indel-19 variant in our group of patients 
with polycystic ovary syndrome were different from 
those found in patients with polycystic ovary syndrome 
of the Brazilian population21. Moreover, there were dif-
ferences among the frequencies of our control group and 
the control group of the Indian population1. In relation 
to the SNP-63, there were also differences when compar-
ing the observed allelic frequencies, both in our group of 
patients with polycystic ovary syndrome and in our con-
trol group, with the frequencies reported in India1. There 
were also differences with the frequencies reported in 
the study conducted in England9 and the study conducted 
on the Spanish population, but in the latter, differences 
were only found among control groups6. Differences found 
in England and India may be due to the little or almost 
no documented migration of the English and Indians to 
Mexico. The analysis of several genetic polymorphisms in 
European and American populations, including Brazil, has 
shown that there is a variation in the genetic structure 
of different populations, possibly as a result of the vari-
ous interethnic combinations31-34. Our results suggest that 
the Mexican mixed race population has particular genetic 
associated with hypercholesterolemia in patients with 
polycystic ovary syndrome10. In Korean women, where 
only 3 variants were analysed (SNP-43, indel-19 and SNP-
63), there was an association between polycystic ovary 
syndrome and haplotype 11122. In this study, since only 
2 variants were analysed, the most frequent haplotype in 
patients with polycystic ovary syndrome was haplotype 21 
(insertion allele of the indel-19 variant, C allele of SNP-
63), which is partially similar to haplotype 121 described 
by Horikawa et al. in the Mexican-American population8. 
Tabla 4 Distribución de haplotipos y diplotipos del SNP-63 
y la variante indel-19 en pacientes con síndrome de ovario 
poliquístico y controles.
Pacientes 
con SOP
Q a
Grupo 
control
Q a
p
 n (%)  n (%)
Haplotipos 21 68 (62) 54 (59) 0.8353
22 25 (23) 21 (23)
11 16 (15) 17 (18)
12 1 (1) 0 (0)
Q  Q 
Diplotipos 21/21 20 (36) 16 (35) 0.8231
21/22 15 (27) 13 (28)
21/11 12 (22) 9 (20)
21/12 1 (2) 0 (0)
22/22 3 (5) 1 (2)
22/11 4 (7) 6 (13)
11/11 0 (0) 1 (2)
SOP: síndrome de ovario poliquístico.
n: número de individuos; SOP: síndrome de ovario poliquístico.
a n: número de cromosomas.
Tabla 3 Distribución de alelos y genotipos del SNP-63 y la variante indel-19 en las pacientes con síndrome de ovario poliquísti-
co y las mujeres del grupo control.
3ROLPRUÀVPR Pacientes con SOP
n (%)
Controles
n (%)
Valor de p OR, IC del 95%
Indel-19 Genotipo Ins/Ins 21 (38) 16 (35) 0.7240 0.831
Del/Ins 27 (49) 22 (48)
Del/Del 7 (13) 8 (17)
Alelo Ins 69 (63) 54 (59) 0.5587 –
Del 41 (37) 38 (41)
SNP-63 Genotipo C/C 38 (69) 30 (65) 0.6793 0.821
C/T 17 (37) 15 (33)
T/T 0 (0) 1 (2)
Alelo C 93 (85) 75 (82) 0.5671 –
T 17 (15) 17 (18)
Del: deleción; n: número de sujetos de estudio (genotipo) o cromosomas (alelo); Ins: inserción; SOP: síndrome de ovario poliquístico.
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